Priya Patel1,2, Sara R Lavoratore3, Jacqueline Flank1, Meaghan Kemp1, Ashlee Vennettilli4, Helen Vol1, Tracey Taylor1, Elyse Zelunka1, Anne Marie Maloney5, Paul C Nathan4,6,7, L Lee Dupuis8,9,10. 1. Department of Pharmacy, The Hospital for Sick Children, Toronto, Canada. 2. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. 3. Rideau Community Health Services, Smith Falls, Canada. 4. Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, 555 University Ave., Toronto, Ontario, M5G 1X8, Canada. 5. Department of Nursing, The Hospital for Sick Children, Toronto, Canada. 6. Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada. 7. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. 8. Department of Pharmacy, The Hospital for Sick Children, Toronto, Canada. lee.dupuis@sickkids.ca. 9. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. lee.dupuis@sickkids.ca. 10. Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, 555 University Ave., Toronto, Ontario, M5G 1X8, Canada. lee.dupuis@sickkids.ca.
Abstract
PURPOSE: Little evidence exists regarding the emetogenicity of chemotherapy in pediatric patients. This study describes the prevalence of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients receiving etoposide plus ifosfamide over 5 days, a common pediatric regimen. METHODS: English-speaking, non-chemotherapy-naïve patients aged 4 to 18 years about to receive etoposide 100 mg/m2/day plus ifosfamide 1800 mg/m2/day over 5 days participated. Antiemetic prophylaxis was determined by each patient's care team. Emetic episodes were recorded and nausea severity was assessed by patients beginning with the first chemotherapy dose, continuing until 24 h after the last chemotherapy dose (acute phase) and ending 7 days later (delayed phase). The proportion of patients experiencing complete acute CINV control (no nausea, no vomiting, and no retching), the primary study endpoint, was described. The prevalence of complete chemotherapy-induced vomiting (CIV) and chemotherapy-induced nausea (CIN) during the acute, delayed, and overall (acute plus delayed) phases; complete delayed and overall CINV control; and anticipatory CINV were also determined. RESULTS: Twenty-four patients participated; acute CINV was evaluable in 22. Most (75%; 18/24) received a 5-HT3 antagonist plus dexamethasone for antiemetic prophylaxis. Few (23%; 5/22) experienced complete acute CINV control. Complete acute CIV and CIN control were experienced by 57% (13/23) and 27% (6/22) of patients, respectively. Complete delayed CINV, CIV, and CIN control rates were 42% (8/19), 70% (14/20), and 42% (8/19), respectively. CONCLUSIONS: Our findings support the classification of etoposide 100 mg/m2/day plus ifosfamide 1800 mg/m2/day IV over 5 days as highly emetogenic. This information will optimize antiemetic prophylaxis selection and CINV control in pediatric patients.
PURPOSE: Little evidence exists regarding the emetogenicity of chemotherapy in pediatric patients. This study describes the prevalence of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients receiving etoposide plus ifosfamide over 5 days, a common pediatric regimen. METHODS: English-speaking, non-chemotherapy-naïve patients aged 4 to 18 years about to receive etoposide 100 mg/m2/day plus ifosfamide 1800 mg/m2/day over 5 days participated. Antiemetic prophylaxis was determined by each patient's care team. Emetic episodes were recorded and nausea severity was assessed by patients beginning with the first chemotherapy dose, continuing until 24 h after the last chemotherapy dose (acute phase) and ending 7 days later (delayed phase). The proportion of patients experiencing complete acute CINV control (no nausea, no vomiting, and no retching), the primary study endpoint, was described. The prevalence of complete chemotherapy-induced vomiting (CIV) and chemotherapy-induced nausea (CIN) during the acute, delayed, and overall (acute plus delayed) phases; complete delayed and overall CINV control; and anticipatory CINV were also determined. RESULTS: Twenty-four patients participated; acute CINV was evaluable in 22. Most (75%; 18/24) received a 5-HT3 antagonist plus dexamethasone for antiemetic prophylaxis. Few (23%; 5/22) experienced complete acute CINV control. Complete acute CIV and CIN control were experienced by 57% (13/23) and 27% (6/22) of patients, respectively. Complete delayed CINV, CIV, and CIN control rates were 42% (8/19), 70% (14/20), and 42% (8/19), respectively. CONCLUSIONS: Our findings support the classification of etoposide 100 mg/m2/day plus ifosfamide 1800 mg/m2/day IV over 5 days as highly emetogenic. This information will optimize antiemetic prophylaxis selection and CINV control in pediatric patients.
Entities:
Keywords:
Chemotherapy-induced nausea and vomiting; Emetogenicity; Etoposide; Ifosfamide; Pediatrics
Authors: L Lee Dupuis; Roy N Tamura; Kara M Kelly; Jeffrey P Krischer; Anne-Marie Langevin; Lu Chen; E Anders Kolb; Nicole J Ullrich; Olle Jane Z Sahler; Eleanor Hendershot; Ann Stratton; Lillian Sung; Thomas W McLean Journal: Pediatr Blood Cancer Date: 2018-12-18 Impact factor: 3.167
Authors: P J Hesketh; M G Kris; S M Grunberg; T Beck; J D Hainsworth; G Harker; M S Aapro; D Gandara; C M Lindley Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: Priya Patel; Paula D Robinson; Jennifer Thackray; Jacqueline Flank; Mark T Holdsworth; Paul Gibson; Andrea Orsey; Carol Portwine; Jason Freedman; Jennifer R Madden; Robert Phillips; Lillian Sung; L Lee Dupuis Journal: Pediatr Blood Cancer Date: 2017-04-28 Impact factor: 3.167
Authors: L Lee Dupuis; Cindy Milne-Wren; Marilyn Cassidy; Maru Barrera; Carol Portwine; Donna L Johnston; Mariana Pradier Silva; Cathryn Sibbald; Michael Leaker; Stacey Routh; Lillian Sung Journal: Support Care Cancer Date: 2009-06-10 Impact factor: 3.603
Authors: L Lee Dupuis; Lillian Sung; Alexander Molassiotis; Andrea D Orsey; Wim Tissing; Marianne van de Wetering Journal: Support Care Cancer Date: 2016-08-26 Impact factor: 3.603
Authors: L Lee Dupuis; Sabrina Boodhan; Mark Holdsworth; Paula D Robinson; Richard Hain; Carol Portwine; Erin O'Shaughnessy; Lillian Sung Journal: Pediatr Blood Cancer Date: 2013-03-19 Impact factor: 3.167
Authors: Damon R Reed; Masanori Hayashi; Lars Wagner; Odion Binitie; Diana A Steppan; Andrew S Brohl; Eric T Shinohara; Julia A Bridge; David M Loeb; Scott C Borinstein; Michael S Isakoff Journal: Cancer Date: 2017-03-21 Impact factor: 6.860